Expert Readers for Your Clinical Trial
our contribution to Clinical Trials
At MD PHARMA SWISS, we specialize in providing top-tier Independent Central Review (ICR) services for clinical trial medical images. Our team comprises subspecialized radiology and image analysis experts who bring precision and expertise to every project.
Our Core Services:
​
Independent Central Review (ICR) of Clinical Trial Medical Images: We offer comprehensive ICR services to ensure accuracy and reliability in medical image assessments.
​
Subspecialized Radiology Expertise: Our team includes experts in various radiology subspecialties, ensuring detailed and specialized image analysis.
Standardized Assessments for Drug and Biologics Development: With the increasing use of medical imaging in multi-center clinical trials, particularly in the pharmaceutical and biotech industry, we provide standardized assessments to minimize variability in image analysis.
​
Dedicated Imaging Core Labs Support: We assist Imaging Core Labs by providing experienced, certified radiologists for the analysis of clinical trial medical images, accommodating the growing demand in this field.
​
MD SWISS PHARMA is at the forefront of integrating advanced imaging modalities and diverse reading methodologies for various therapeutic indications. Our quantitative assessment capabilities are extensive, including but not limited to oncology response criteria such as RECIST 1.0/1.1, Cheson/Lugano, RANO/McDonald, Choi, and PCWG2.
At MD SWISS PHARMA, we specialize in the cutting-edge analysis of whole-body MRI scans and biomarkers, offering a comprehensive approach to screening and early detection of health conditions. Our services are designed to provide a detailed and holistic understanding of your health, employing the latest advancements in medical imaging and biomarker research.
High-Resolution Imaging: Our whole-body MRI protocols utilize the latest technology to provide high-resolution images, allowing for the segmentation of muscle volume and fat (subcutaneous and visceral).
Non-Invasive Procedure: MRI screening is a non-invasive process, free from radiation exposure, making it a safe choice for regular health assessments.
Early Detection of Diseases: This technique is particularly effective in the early detection of a range of conditions, including cancers, musculoskeletal disorders, and vascular diseases.
Personalized Health Insights: We tailor the MRI screening to individual health needs, offering personalized insights into your health.
Cutting-Edge Biomarker Testing: We conduct comprehensive biomarker tests to identify early signs of diseases at the molecular level.
Predictive Health Information: Biomarkers can provide predictive information about your health, helping to identify potential health risks before they become serious.
Guiding Treatment Decisions: The combined insights from biomarker and MRI analysis can guide personalized health program, diet and preventive measures.
At MD SWISS PHARMA, our findings underscore the importance of a holistic radiological approach in preventive healthcare, providing insights for both early-stage disease management and proactive lifestyle adjustments. Trust us to be your partners in proactive health management and early disease detection.
